Search Within

Sujata Patil

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (30)
  2. Meeting Abstract (28)
Groups
  1. Biostatistics Service (58)
  2. Epidemiology and Biostatistics (58)
  3. Human Oncology and Pathogenesis Program (58)
  4. Department of Medicine (56)
  5. Solid Tumor Oncology Division (56)
  6. GSK Faculty (50)

More Groups

People
  1. Sarat Chandarlapaty (28)
  2. Clifford Hudis (27)
  3. Shanu Modi (24)
  4. Martin Voss (19)
  5. Robert Motzer (19)
  6. Abraham Hakimi (18)

More People

Years
  1. 2022 (2)
  2. 2021 (6)
  3. 2020 (3)
  4. 2019 (7)
  5. 2018 (2)
  6. 2017 (4)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Cancer Research (11)
  3. Clinical Cancer Research (7)
  4. Clinical Breast Cancer (3)
  5. Clinical Genitourinary Cancer (3)
  6. Annals of Surgical Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. American Society of Clinical Oncology (17)
  3. Elsevier Inc. (6)
  4. Nature Publishing Group (3)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (58)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • PIK3CA and AKT1 mutations are independent in invasive breast cancer
    Meeting Abstract

    Moynahan, M. E.; Heguy, A.; Drobnjak, M.; Traina, T.; Howard, J.; Patil, S.; Gerald, W.; Solit, D.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • PIK3CA mutation associates with improved outcome in breast cancer
    Journal Article

    Kalinsky, K.; Jacks, L.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U. K.; Hedvat, C. V.; Traina, T. A.; Solit, D.; Gerald, W.; more...
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save